1-16 of 16
Alwin D.R. Huitema
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol

Jade M. van Berge Henegouwen, Laurien J. Zeverijn, Birgit S. Geurts, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Alwin D.R. Huitema, Filip Y.F. de Vos, Katrien Grünberg, Haiko J. Bloemendal, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3937–3943.
https://doi.org/10.1158/1078-0432.CCR-23-3917
Published: 03 September 2024
View article titled, Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Open the PDF for Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol in another window
Includes: Supplementary data
Journal Articles

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma

Alaa Embaby, Sanne C.F.A. Huijberts, Liqin Wang, Rodrigo Leite de Oliveira, Hilde Rosing, Bastiaan Nuijen, Joyce Sanders, Ingrid Hofland, Charlaine van Steenis, Roelof J.C. Kluin, Cor Lieftink, Christopher G. Smith, Christian U. Blank, Johannes V. van Thienen, John B.A.G. Haanen, Neeltje Steeghs, Frans L. Opdam, Jos H. Beijnen, Alwin D.R. Huitema, Rene Bernards, Jan H.M. Schellens, Sofie Wilgenhof
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3157–3166.
https://doi.org/10.1158/1078-0432.CCR-23-3171
Published: 01 August 2024
View article titled, A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <em>BRAF</em><sup><em>V600</em></sup>-Mutated Melanoma
Open the PDF for A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <em>BRAF</em><sup><em>V600</em></sup>-Mutated Melanoma in another window
Includes: Supplementary data
Journal Articles

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

Louisa R. Hoes, Jade M. van Berge Henegouwen, Hanneke van der Wijngaart, Laurien J. Zeverijn, Daphne L. van der Velden, Joris van de Haar, Paul Roepman, Wendy J. de Leng, Anne M.L. Jansen, Erik van Werkhoven, Vincent van der Noort, Alwin D.R. Huitema, Eelke H. Gort, Jan Willem B. de Groot, Emile D. Kerver, Derk Jan de Groot, Frans Erdkamp, Laurens V. Beerepoot, Mathijs P. Hendriks, Egbert F. Smit, Winette T.A. van der Graaf, Carla M.L. van Herpen, Mariette Labots, Ann Hoeben, Hans Morreau, Martijn P. Lolkema, Edwin Cuppen, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1402–1411.
https://doi.org/10.1158/1078-0432.CCR-21-3752
Published: 01 April 2022
View article titled, Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Open the PDF for Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment in another window
Includes: Supplementary data
Journal Articles

Precision Dosing of Targeted Therapies Is Ready for Prime Time

Stefanie L. Groenland, Remy B. Verheijen, Markus Joerger, Ron H.J. Mathijssen, Alex Sparreboom, Jos H. Beijnen, Jan H. Beumer, Neeltje Steeghs, Alwin D.R. Huitema
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6644–6652.
https://doi.org/10.1158/1078-0432.CCR-20-4555
Published: 15 December 2021
View article titled, Precision Dosing of Targeted Therapies Is Ready for Prime Time
Open the PDF for Precision Dosing of Targeted Therapies Is Ready for Prime Time in another window
Journal Articles

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir

Vincent A. de Weger, Frederik E. Stuurman, Stijn L.W. Koolen, Johannes J. Moes, Jeroen J.M.A. Hendrikx, Emilia Sawicki, Bas Thijssen, Marianne Keessen, Hilde Rosing, Marja Mergui-Roelvink, Alwin D.R. Huitema, Bastiaan Nuijen, Jos H. Beijnen, Jan H.M. Schellens, Serena Marchetti
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5466–5474.
https://doi.org/10.1158/1078-0432.CCR-17-2299
Published: 13 September 2019
View article titled, A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir
Open the PDF for A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir in another window
Journal Articles

Individualized Pazopanib Dosing—Response

Remy B. Verheijen, Alwin D.R. Huitema, Neeltje Steeghs
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6299.
https://doi.org/10.1158/1078-0432.CCR-16-2297
Published: 15 December 2016
View article titled, Individualized Pazopanib Dosing—Response
Open the PDF for Individualized Pazopanib Dosing—Response in another window
Journal Articles

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

Remy B. Verheijen, Sander Bins, Ron H.J. Mathijssen, Martijn P. Lolkema, Leni van Doorn, Jan H.M. Schellens, Jos H. Beijnen, Marlies H.G. Langenberg, Alwin D.R. Huitema, Neeltje Steeghs
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5738–5746.
https://doi.org/10.1158/1078-0432.CCR-16-1255
Published: 30 November 2016
View article titled, Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients
Open the PDF for Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients in another window
Journal Articles

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

Didier Meulendijks, Ulrik N. Lassen, Lillian L. Siu, Alwin D.R. Huitema, Vaios Karanikas, Morten Mau-Sorensen, Derek J. Jonker, Aaron R. Hansen, Mary E. Simcox, Kathleen J. Schostack, Dean Bottino, Hua Zhong, Markus Roessler, Suzana M. Vega-Harring, Tiantom Jarutat, David Geho, Karen Wang, Mark DeMario, Glenwood D. Goss, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 858–867.
https://doi.org/10.1158/1078-0432.CCR-15-1506
Published: 14 February 2016
View article titled, Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
Open the PDF for Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors in another window
Journal Articles

Cytolytic Virus Activation Therapy for Epstein-Barr Virus–Driven Tumors

Maarten A. Wildeman, Zlata Novalić, Sandra A.W.M. Verkuijlen, Hedy Juwana, Alwin D.R. Huitema, I. Bing Tan, Jaap M. Middeldorp, Jan Paul de Boer, Astrid E. Greijer
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (18): 5061–5070.
https://doi.org/10.1158/1078-0432.CCR-12-0574
Published: 16 September 2012
View article titled, Cytolytic Virus Activation Therapy for Epstein-Barr Virus–Driven Tumors
Open the PDF for Cytolytic Virus Activation Therapy for Epstein-Barr Virus–Driven Tumors in another window
Includes: Supplementary data
Journal Articles

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group

Markus Joerger, Alwin D.R. Huitema, Dick J. Richel, Christian Dittrich, Nikolas Pavlidis, Evangelos Briasoulis, Jan B. Vermorken, Elena Strocchi, Andrea Martoni, Roberto Sorio, Henk P. Sleeboom, Miguel A. Izquierdo, Duncan I. Jodrell, Hilary Calvert, Alan V. Boddy, Harry Hollema, Regine Féty, Wjf J.F. Van der Vijgh, Georg Hempel, Etienne Chatelut, Mats Karlsson, Justin Wilkins, Brigitte Tranchand, Ad H.G.J. Schrijvers, Christian Twelves, Jos H. Beijnen, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6410–6418.
https://doi.org/10.1158/1078-0432.CCR-07-0064
Published: 01 November 2007
View article titled, Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group
Open the PDF for Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group in another window
Journal Articles

CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity

Anthe S. Zandvliet, Alwin D.R. Huitema, William Copalu, Yasuhide Yamada, Tomohide Tamura, Jos H. Beijnen, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (10): 2970–2976.
https://doi.org/10.1158/1078-0432.CCR-06-2978
Published: 15 May 2007
View article titled, CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity
Open the PDF for CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity in another window
Journal Articles

A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer

Denis C. Talbot, Joachim von Pawel, Emma Cattell, S. Murray Yule, Claire Johnston, Anthe S. Zandvliet, Alwin D.R. Huitema, Chris J. Norbury, Paul Ellis, Leon Bosquee, Martin Reck
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1816–1822.
https://doi.org/10.1158/1078-0432.CCR-06-0249
Published: 15 March 2007
View article titled, A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function

Corine Ekhart, Milly E. de Jonge, Alwin D.R. Huitema, Jan H.M. Schellens, Sjoerd Rodenhuis, Jos H. Beijnen
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (21): 6502–6508.
https://doi.org/10.1158/1078-0432.CCR-05-1076
Published: 03 November 2006
View article titled, Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function
Open the PDF for Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function in another window
Journal Articles

Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel

Tessa M. Bosch, Alwin D.R. Huitema, Valerie D. Doodeman, Robert Jansen, Els Witteveen, Wim M. Smit, Rob L. Jansen, Carla M. van Herpen, Marcel Soesan, Jos H. Beijnen, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5786–5793.
https://doi.org/10.1158/1078-0432.CCR-05-2649
Published: 04 October 2006
View article titled, Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel
Open the PDF for Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel in another window
Journal Articles

Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors

Markus Joerger, Alwin D.R. Huitema, Desiree H.J.G. van den Bongard, Jan H.M. Schellens, Jos H. Beijnen
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 2150–2157.
https://doi.org/10.1158/1078-0432.CCR-05-2069
Published: 11 April 2006
View article titled, Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors
Open the PDF for Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors in another window
Journal Articles

Accuracy, Feasibility, and Clinical Impact of Prospective Bayesian Pharmacokinetically Guided Dosing of Cyclophosphamide, Thiotepa, and Carboplatin in High-Dose Chemotherapy

Milly E. de Jonge, Alwin D.R. Huitema, Annemarie C. Tukker, Selma M. van Dam, Sjoerd Rodenhuis, Jos H. Beijnen
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (1): 273–282.
https://doi.org/10.1158/1078-0432.273.11.1
Published: 21 January 2005
View article titled, Accuracy, Feasibility, and Clinical Impact of Prospective Bayesian Pharmacokinetically Guided Dosing of Cyclophosphamide, Thiotepa, and Carboplatin in High-Dose Chemotherapy
Open the PDF for Accuracy, Feasibility, and Clinical Impact of Prospective Bayesian Pharmacokinetically Guided Dosing of Cyclophosphamide, Thiotepa, and Carboplatin in High-Dose Chemotherapy in another window